Sergio Fazio, MD, PhD
Eliot Brinton, MD, FAHA, FNLA
Michael Miller, MD
Margo Minissian, PhD, ACNP
John R. Nelson, MD, FACC, FNLA, FASNC
Dialogues from the Dais: CVD Risk Red...
December 10, 2020
07:00 PM - 08:30 PM CST
Ewa A. Jankowska, MD, PhD, FESC
AFFIRM-AHF: Key Takeaways
Stefan D. Anker, MD, PhD
Javed Butler, MD, MPH, MBA
Josep Comin-Colet, MD, PhD
Late-breaking First Response on AFFIRM-AHF
Erin D. Michos, MD, MHS, FACC, FAHA, FASE
Prevention of ASCVD in Women Through Lipid Management in the New Era
Peter van der Meer, MD, PhD
Common Misconceptions About Iron Deficiency in Heart Failure and What to Do A...
Mikhail Kosiborod, MD
CARE HK in HF: Designing a Real-world Study to Identify Barriers to Guideline...
George Bakris, MD
Matthew R. Weir, MD
Faiez Zannad, MD, PhD
Potassium Management Made Easy
Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
Management of Heart Failure: Time to Consider New Options?
Michel Farnier, MD, PhD
Børge G. Nordestgaard, MD, DMSc
Omega-3 Fatty Acids in Patients with ASCVD Risk: The Role of Icosapent Ethyl ...
Christopher P. Cannon, MD
Samuel Dagogo-Jack, MD, DSc
Is It Time to Change Your Treatment Strategy for Type 2 Diabetes Patients wit...
Beyond Anemia: Understanding the Significance and Treatment of Iron Deficiency
Mr. Jackson Moves to Town: Overcoming Challenges to Optimizing RAASi Therapy
Robert J. Mentz, MD
Piotr Ponikowski, MD, PHD, FESC, FHFA
Don’t Be Fooled: It’s Not Just Anemia, It’s Iron Deficiency
Mechanisms in Heart Failure: Why Iron Deficiency Matters
Balancing RAASi Therapy and Potassium: Understanding How it Works
Practical Considerations to Manage Residual ASCVD Risk